Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | SSX2 |
| Gene Name: | SSX2 |
| Protein Full Name: | Protein SSX2 |
| Alias: | SSX2A; Synovial sarcoma, X breakpoint 2 |
| Mass (Da): | 21620 |
| Number AA: | 188 |
| UniProt ID: | Q16385; Q8IZG3; Q8IZG4 |
| Locus ID: | 6757 |
| COSMIC ID: | SSX2 |
| Gene location on chromosome: | Xp11.22 |
| Cancer protein type: | ?TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19535 |
| Percent of cancer specimens with mutations: | 0.02 |
| Deregulated in translocations: | t(X;18)(p11.2;q11.2); SYT-SSX1, SYT-SSX2, SYT-SSX4; the exon 10 of the SS18 (SYT) gene is fused to exon 6 of the SSX genes; The last 8 amino acid residues of the SS18 (SYT) protein are replaced by 78 amino acids from the C-terminal part of SSX proteins. |
| Normal role description: | Transcription factor involved in germ-line development. It functions to silence genes via chromatin remodeling. SSX is also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and SSX2 is a potentially useful target in cancer vaccine immunotherapy. ISSX2 is implicated in the fusion protein SYT-SSX in synovial sarcoma. Mechanism of oncogenesis unclear, perhaps hybrid gene confers loss of function to SSX. |